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Rapid innovation in (epi)genetics and biomarker sciences is driving a new drug
development and product development pathway, with the personalized medicine
era dominated by biologic therapeutics and companion diagnostics. Companion
diagnostics (CDx) are tests and assays that detect biomarkers and specific mutations
to elucidate disease pathways, stratify patient populations, and target drug therapies.
CDx can substantially influence the development and regulatory approval for certain
high-risk biologics. However, despite the increasingly important role of companion
diagnostics in the realization of personalized medicine, in the USA, there are only 23
Food and Drug Administration (FDA) approved companion diagnostics on the market
for 11 unique indications. Personalized medicines have great potential, yet their use
is currently constrained. A major factor for this may lie in the increased complexity of
the companion diagnostic and corresponding therapeutic development and adoption
pathways. Understanding the market dynamics of companion diagnostic/therapeutic
(CDx/Rx) pairs is important to further development and adoption of personalized
medicine. Therefore, data collected on a variety of factors may highlight incentives or
disincentives driving the development of companion diagnostics. Statistical analysis
for 36 hypotheses resulted in two significant relationships and 34 non-significant
relationships. The sensitivity of the companion diagnostic was the only factor that
significantly correlated with the price of the companion diagnostic. This result indicates
that while there is regulatory pressure for the diagnostic and pharmaceutical industry
to collaborate and co-develop companion diagnostics for the approval of personalized
therapeutics, there seems to be a lack of parallel economic collaboration to incentivize
development of companion diagnostics.
Keywords: companion diagnostic, combinational therapy, risk:benefit appraisal, healthcare risk management,
personalized medicine, stratified medicine, healthcare translation, clinical adoption
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INTRODUCTION
Cures for age-related diseases such as cardiovascular disease,
diabetes mellitus, Alzheimer’s disease, and cancer, are
increasingly unlikely to come from historic pharmaceutical
industry models of therapeutic innovation and development.
While the standard model of drug R&D utilized by
pharmaceuticals has produced eﬀective treatments to manage
such diseases as hypertension, asthma, and arthritis, highly
variable and increasingly more complex diseases such as
cancer will require much more personalized approaches
to patient treatment. The future of medicine, fueled by
growth in complex biological data, lack of innovation in
current pipelines, and political pressure, has therefore been
shifting toward personalized medicine (La Thangue and Kerr,
2011). Personalized medicine, as deﬁned by the National
Academies Press, is “the ability to classify individuals into
subpopulations that diﬀer in their susceptibility to a particular
disease or their response to a speciﬁc treatment. Preventive or
therapeutic interventions can then be concentrated on those
who will beneﬁt, sparing expense and side eﬀects for those
who will not” (La Thangue and Kerr, 2011). Speciﬁcally in
personalized medicine, there has been an increasing focus
on the barriers to widespread adoption (Brindley et al.,
2015). The current literature highlights cost-eﬀectiveness,
eﬃcacy, reimbursement, and regulation (Davies et al., 2014;
French et al., 2014) as the key concerns for adoption of
current personalized medicines, but an aspect of personalized
medicine that has recently come into the spotlight as an
inseparable aspect of precision medicine is the role of companion
diagnostics.
Companion diagnostics (CDx) are a critical component in
advancing personalized medicine. Companion diagnostics
were oﬃcially deﬁned in 2014 by the Food and Drug
Administration (FDA; Silver Springs, MD, USA) as “a
medical device, often an in vitro device, which provides
information that is essential for the safe and eﬀective use
of a corresponding drug or biological product” (Center
for Devices and Radiological Health, 2015b). Biomarker
based stratiﬁcation assays designed to identify responsive
patient subpopulations and detect patients more likely
to experience adverse eﬀects are becoming increasingly
important to securing market share for high eﬃcacy, high cost
therapeutics (Amir-Aslani and Mangematin, 2010; Yip et al.,
2015).
From a pharmaceutical development viewpoint, CDxs can
contribute to the successful approval and market launch
of high-risk but high beneﬁt therapeutics. The success
of Herceptin (Trastuzumab; Roche, Basel, Switzerland),
a monoclonal antibody (mAb) that blocks the growth of
malignant tumor cells, relies on the ability of a CDx to
accurately identify the subpopulation (22%) of patients
with HER2-positive early breast cancer (Trusheim et al.,
2011). Failure to stratify the patient population will result
in both costly interventions and unnecessary exposure to
increased cardiotoxicities for patients who cannot beneﬁt from
the drug.
Herceptin was groundbreaking as the ﬁrst targeted therapy
to address the underlying causes of a predominantly age-
related disease, and its CDx, HercepTest (Dako, Glostrup,
Denmark), was the ﬁrst CDx to enter clinical practice in 1998
[“Genentech: Herceptin R© (trastuzumab) Development Timeline,
n.d.”]. However, few companion diagnostics/treatment (CDx/Rx)
pairs have been approved for the market since Herceptin’s
breakthrough (Jakka and Rossbach, 2013; Davies et al., 2014).
There have been a limited total of 23 approved CDx for 11
personalized therapies and seven primary indications in the past
17 years (Center for Devices and Radiological Health, 2015a).
The rates of technological development and clinical adoption of
CDxs has been arguably limited relative to the extent of public
and private investment.
Limited progress could be due to a number of reasons.
There are numerous scientiﬁc challenges to the discovery
and production of companion diagnostics and corresponding
therapeutics (De Lecea and Rossbach, 2012). Equally important
to the advancement of personalized therapies, however,
are signiﬁcant regulatory and economic challenges (Davis
et al., 2009; Djalalov et al., 2011; Jakka and Rossbach,
2013).
Regulation for CDx and Rx is intrinsically connected, and
this relationship may or may not be reﬂected in the economic
incentives and disincentives driving innovation and development
of CDx/Rx pairs. The FDA recently released the “In Vitro
Companion Diagnostic Devices: Guidance for Industry and Food
and Drug Administration Staﬀ” on July 31st, 2014, suggesting
that companion diagnostics and corresponding therapeutics be
co-developed and evaluated concurrently (Guidance for Industry
and Food and Drug Administration Staﬀ, 2014).
This suggested regulatory link between companion
diagnostics and their corresponding drugs can inﬂuence
economic factors and aﬀect the rate of market approval and
adoption (Hinman et al., 2008; Yip et al., 2015). Speciﬁcally,
the collaboration between two typically independent industries
potentially presents challenges in aligning incentives between
diagnostic developers and pharmaceutical manufacturers
(Chiang and Million, 2011; Jørgensen, 2013). Figure 1 shows
the regulatory framework that underpins co-development.
To date, the regulatory landscape for market approval and
price determinations of CDx/Rx pairs is relatively unexamined
and lacking quantitative analysis necessary for changes and
improvements.
Therefore, it is important to analyze current, publically
available data for companion diagnostics and corresponding
therapeutics to identify drivers, limitations, and areas for
more research in the current landscape. A systematic
analysis and numerical data will identify factors aﬀecting
the CDx/Rx pair market and provide more information to
assess the impact of future regulatory and policy changes
in facilitating or limiting the development of companion
diagnostics. This paper provides a data driven analysis
of the CDx/Rx market by statistically analyzing and
discussing factors that may incentivize, restrict, or create
uncertainty in the development and adoption of companion
diagnostics.
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FIGURE 1 | Companion diagnostic development and regulation concomitant with drug therapy development and regulation. The relationship between a
companion diagnostic and therapeutic is unique and economic effects of co-development have yet to be fully realized.
MATERIALS AND METHODS
Inclusion Criteria
A systematic analysis was conducted with methodology set in
Figure 2. Seven sets of personalized therapies were selected
for analysis based on a series of case studies of personalized
medicines and their CDx published in Meadows et al. (2015).
These cases describe a number of indications over a period
of 15 years; although not a comprehensive list, they represent
a number of leading examples of successful stratiﬁcation of
therapeutics. While there are 23 FDA approved CDx for
11 personalized therapeutics, the availability of established,
validated, and publically accessible data, along with the existence
of robust prior research, limits the number of CDx/Rx pair
available for examination to the seven personalized therapeutics
presented in previous literature (Meadows et al., 2015). The
majority of CDx/Rx pairs presented were in the ﬁeld of oncology,
such as Herceptin, Xalkori, Zelboraf (vemurafenib; Roche, Basel,
Switzerland), and Vectibix (Panitumumab; Amben, CA, USA).
Oncology contributes a large proportion of CDx/Rx due to its
inherently highly stratiﬁed populations and extensive investment
in biomarker discovery, but the development of companion
diagnostics is not limited to oncological indications. Therefore,
ﬁnal list of CDx/Rx pairs attempts to capture multiple primary
indications, including CDx/Rx pairs beyond those on the “List
of FDA Approved Companion Diagnostics” (Center for Devices
and Radiological Health, 2015a) to include the three highly
personalized therapeutics and unoﬃcial companion diagnostics
examined in Meadows et al. (2015): Ziagen (abacavir sulfate;
Viiv Healthcare, Brentford, UK), Selzentry (Maraviroc; Viiv
Healthcare, Brentford, UK), and Kalydeco (Vertex, Cambridge,
MA, USA). All three additional CDx/Rx pairs address indications
(cystic ﬁbrosis and HIV) in which speciﬁc mutations and
tropisms are known at time of diagnosis and extensive
prior literature is available to support their classiﬁcation as
personalized therapeutics (Meadows et al., 2015).
Table 1 shows the ﬁnalized table of companion and pseudo-
companion diagnostic and therapeutic pairs that meet the
requirements of a large clinical database, pre-existing research,
long duration on market, robust data, and US market approval.
A list of feasible factors impacting the companion diagnostic
industry available for systematic assessmentwas determined from
a preliminary overview of existing research (Trusheim et al.,
2011) for each of the seven personalized therapeutics in Table 1.
Nine factors were analyzed that could inﬂuence companion
diagnostic development and adoption: CDx price, CDx
sensitivity, price of drug standardized per course of treatment,
duration of drug treatment, years on the market for drug
(measured from year of FDA approval to year of patent
expiration, or predicted patent expiration for drugs most likely
to receive extended protection), drug eﬃcacy, total current
population of patients in speciﬁc indication, subpopulation of
patient population (calculated with the percentage of total patient
population predicted to have the speciﬁc mutation or biomarker
expression), and response rate of patient subpopulation to drug
after selection with companion diagnostic.
Factors impacting both the companion diagnostic
manufacturers (price of CDx, sensitivity, total patient
population) and pharmaceutical therapy development and
adoption (drug prices, eﬀectiveness, patient subpopulation,
response rate) were included as factors for CDx market analysis
because of the unique regulatory dependency of CDx and
personalized therapeutic. The factor “price of drug” was
standardized as the total cost for one course of complete
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FIGURE 2 | Graphical representation of methodology. Analysis proceeded in a stepwise fashion.
treatment. “Drug eﬃcacy” was based on the percentage reported
in clinical trials of the drug to either decrease tumor size or
reach a standard endpoint such cell count and forced expiratory
volume in 1 s. Factors fell into two categories – those relating to
the CDx (CDx price, CDx sensitivity) solely and those relating to
the therapeutic and treatment (drug price, duration of treatment,
years the drug has been on market, drug eﬀectiveness, total
patient population, treatable subpopulation, response rate).
Data Collection and Statistical Analysis
Data in each category for each therapy was individually
obtained from eighty distinct sources, ranging from literature
searches in PubMed, personal correspondence with diagnostic
and pharmaceutical company representatives, current articles in
prominent news journals, government dockets, annual reports,
patent ﬁlings, Internet searches, and published regulatory agency
documents, to oﬃcial FDA released drug labels. Data for
factors in the therapeutic market was applied to each CDx. For
example, the numerical value for total population of patients
with breast cancer was identical for each of Herceptin’s six FDA
approved CDx.
Statistical analysis was conducted using JMP. The relationship
between two factors was determined by Spearman’s Rho, a non-
parametric tool to determine correlation for data without a
Gaussian distribution. Signiﬁcant relationships were determined
by t-test on regression, with a null hypothesis that the regression
is zero. Results were considered signiﬁcant if p < 0.05.
Relationships for all possible pairs of factors were tested in
order to preserve an unbiased analysis. Statistical analysis was
supplemented with detailed case studies examining competition
within the CDx landscape in the two CDx/Rx pairs with multiple
FDA approved CDx at the time of this assessment (Herceptin
with six CDx and Vectibix with three CDx).
RESULTS
Statistical analysis for 36 hypotheses resulted in two signiﬁcant
relationships and 34 non-signiﬁcant relationships. Table 2 shows
the nine by nine matrix of factor pairs with calculated r- and
p-values. Further analysis focuses on possible interpretations
of insigniﬁcant and signiﬁcant relationships for companion
diagnostics, with less focus on relationships for the therapeutic
market.
Relationships Affecting Companion
Diagnostics
The factors that relate to the companion diagnostic have a
signiﬁcant relationship between themselves: the CDx price has
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TABLE 1 | Select list of FDA approved personalized therapeutic/CDx pairs.
Primary indication Drug (pharma) CDx/approved year (diagnostic company) Assay
Breast cancer Herceptin (Roche, Basel,
Switzerland)
HercepTest/1998 (Dako, Glostrup, Denmark) SemiqIHC
SPOT-light HER-2 CISH Kit/2008 (Life Technologies, South San Francisco, CA, USA) CISH
Bond Oracle Her2 INC System/2012 (Leica Biosystem, Nussloch, Germany) SemiqIHC
PATHVYSION HER-2 DNA Probe Kit/2013 (Abbott, IL, USA) FISH DNA Probe
HER2 FISH PharmDx Kit/2005 (Dako) qFISH
INFORM HER2 Dual ISH/2011 (Roche) CISH
Melanoma Zelboraf (Roche) COB AS 4800 BRAF V600 Mutation Test/2013 (Roche) RT-PCR
Non-small cell lung cancer Xalkori (Pfizer, NY, USA) Lysis ALK Break Apart FISH Probe Kit/2013 (Abbott) FISH
Colorectal Cancer Vectibix (Amgen, CA, USA) Therascreen KRAS RGQ PCR Kit/2011 (Qiagen, Venlo, The Netherlands) PCR
The cobas KRAS Mutation Test/2013 (Roche) RT-PCR
EGFR PharmDx Kit/2003 (Dako) qlHC
Cystic fibrosis Kalydeco (Vertex, MA, USA) Unbranded laboratory test used during (1989) Clinical trials
Human immunodeficiency
virus (HIV)
Ziagen (Viiv Healthcare,
Brentford, UK)
LDTs at time of development (2007)
Human immunodeficiency
virus (HIV)
Selzentry (Viiv Healthcare) Trofile Test/2008 (Labcorp, NC, USA) qPCR
Selection of data was based on availability of data, robust prior research, large clinical database, and US market approval.
SemiqIHC, semiquantitative immunohistochemistry; CISH, chromogenic in situ hybridization; FISH, fluorescence in situ hybridization; qFISH, quantitative fluorescence
in situ hybridization; RT-PCR, real-time polymerase chain reaction; qPCR, quantitative polymerase chain reaction.
TABLE 2 | Correlation (r) and significance (p) values for financial and product factors affecting the market for companion diagnostic/therapeutic
(CDx/Rx) pairs.
CDx
price
CDx
sensitivity
Drug price
(treatment)
Duration
of
treatment
Drug
years on
market
Drug
effective-
ness
Total
patient
population
Treatable
subpopulation
Response
rate
CDx price 1 −0.78 0.18 0.31 −0.54 −0.26 0.25 −0.25 0.07
0 0.04 0.7 0.5 0.22 0.57 0.59 0.59 0.88
CDx sensitivity 1 0.18 −0.44 −0.04 −0.32 0.2 −0.14 −0.14
0 0.7 0.33 0.94 0.48 0.67 0.76 0.76
Drug price
(treatment)
1 0.55 0.51 −0.71 −0.31 −0.36 0.46
0 0.2 0.25 0.07 0.5 0.43 0.29
Duration of
treatment
1 −0.49 −0.29 −0.13 −0.04 0.45
0 0.27 0.53 0.78 0.94 0.31
Drug years on
market
1 0.29 −0.3 −0.21 0.11
0 0.53 0.51 0.66 0.81
Drug
effectiveness
1 0.41 0.29 0.18
0 0.36 0.53 0.7
Total patient
population
1 0.88 0.11
0 0.01 0.82
Treatable
subpopulation
1 0.29
0 0.53
Response rate 1
0
Thirty-six factors were statistically analyzed using Spearman’s rank test on JMP. Relationships were significant if p < 0.05. Significant relationships are bolded and
underlined. Gray box is correlation while white box is significance.
a signiﬁcant relationship with the CDx sensitivity. Figure 3A
shows this relationship graphically, with rho calculated as a
Spearman’s rank correlation that standardizes outliers as opposed
to a Pearson’s correlation for Gaussian distributions (r = −0.78,
p = 0.04). One explanation for the price of CDx increasing
with increasing sensitivity is that a CDx which can more
accurately stratify the patient population into correct respondent
groups might take longer to develop, or utilize more expensive
technology, and therefore be priced higher to oﬀset the higher
costs of development.
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FIGURE 3 | Significant relationships and non-significant relationships for CDx price. (A) There is a significant relationship between CDx price and the
duration of drug treatment (R2 = 0.347, p = 0.026) and a significant relationship (B) between CDx price and CDx sensitivity (R2 = 0.507, p = 0.004). (C) There is a
non-significant relationship between CDx price and revenue of drug (R2 = 0.171, p = 0.140) and the total patient population (R2 = 0.105, p = 0.256).
The factors that relate solely to the companion diagnostic
(CDx price, CDx sensitivity) do not have signiﬁcant relationships
to factors relating to the therapeutic or treatment (drug price for
treatment, years on market for drug, drug eﬃcacy, population
measurements, and response rates to drug). One may expect
a signiﬁcant relationship to exist between the factors aﬀecting
companion diagnostics and the therapeutic or treatment because
of their interconnected nature and regulatory co-development.
For instance, it may be expected that companion diagnostics
would follow the same pricing curve as their corresponding
therapeutic, because there are costs involved in meeting
regulatory standards (Quinn, 2010). A high risk, high beneﬁt
therapeutic such as Zelboraf will be priced to reﬂect the time,
cost, and production of larger clinical trials, more advanced
technology, and longer development time and because the
companion diagnostic used during clinical trials for Zelboraf
faces a similar regulatory pathway, it might be expected to be
priced accordingly. However, there is no signiﬁcant relationship
between CDx price and the drug price for a complete course
of treatment (r = 0.18, p = 0.7, Figure 3B). Zelboraf costs
approximately $56,400 per treatment (Cohen and Felix, 2014)
with a CDx priced at $401, while Vectibix costs $68,000 per
treatment (Pollack, 2006) – more than Zelboraf – but with a CDx
priced lower than $401, at $385 (Ray, 2013). In another instance,
it may be expected that CDx price will have a relationship with
the treatable subpopulation because the treatable population is a
representation of the full market size that a CDx could penetrate.
However, market size, measured by the total patient population,
does not statistically have a signiﬁcant relationship with the price
of a CDx (r = 0.25, p = 0.59, Figure 3C). The lack of signiﬁcant
relationships raises more research questions and limitations are
further discussed in Section “Limitations.”
Competition
Examining competition in two case studies of Herceptin and
Vectibix revealed that as the number of CDx for one therapeutic
increases, sensitivity improves. Since the approval of the ﬁrst
companion diagnostic, there have been a growing number of
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companion diagnostics each year, with an expanding range
of pricing and more diverse test types (Figures 4 and 5). In
the case study of Herceptin, the price range of companion
diagnostics heightened with the expansion of testing methods,
and accordingly, sensitivity increased as technology improved
through the years (Figure 6).
In the case study of Vectibix, the companion diagnostic
followed a unique developmental pathway that ultimately led
to better identiﬁcation of the patient population that responded
positively to anti-EGFR therapy. Originally, overexpression of
EGFR was discovered as a biomarker for colorectal cancer
and enlisted in clinical trials for an anti-EGFR mAb, Erbitux.
Following the model of Herceptin, patients enrolled in Erbitux
clinical studies had to demonstrate immunohistochemistry (IHC)
evidence of positive EGFR expression, leading to the co-
development of Dako’s EGFR pharmDxTM test [Genentech:
Herceptin R© (trastuzumab) Development Timeline, n.d.].
In 2007, following the model set by Herceptin and HER2,
Erbitux and its companion diagnostic were co-approved.
However, unlike the smooth success of Herceptin, subsequent
studies post-drug approval failed to support the correlation
between EGFR overexpression and response to either Erbitux,
or a second anti-EGFR drug in development, Vectibix
(Cunningham et al., 2004; Saltz et al., 2004). In a parallel
set of studies, a better predictor of response to Erbitux and
Vectibix started emerging. Pivotal studies conducted on the
clinical utility of a KRAS mutation status conﬁrmed the KRAS
gene as an accurate predictor of non-responsive individuals to
anti-EGFR therapy (Lievre et al., 2006). The FDA acknowledged
the evidence base for KRAS presence as a marker for patients
who would achieve no beneﬁt from anti-EGFR therapy and
issued a label update for the entire class of drugs, recommending
KRAS testing as part of colorectal cancer patient management
(Amado et al., 2008).
Subsequent approval of Vectibix and corresponding
companion diagnostic, Qiagen’s (Venlo, The Netherlands)
therascreen KRAS RGQ PCR kit, followed (Ray, 2014). Two
years later, Roche developed the cobas R© KRAS Mutation kit; a
companion diagnostic comparable to Qiagen’s therascreen, but
one that produces faster results, but at a higher price (Gonzalez
de Castro et al., 2012).
DISCUSSION
Quantitatively assessing the relationship between factors aﬀecting
the market for companion diagnostics and corresponding
therapeutics reveals that the regulatory codependence of CDx/Rx
pairs is not reﬂected in their economic landscape. With
CDx/Rx development, the two separate industries (diagnostic
and pharmaceutical) form a relationship in which FDA
approval, reimbursement, and prescription of the therapeutic is
dependent on accurate stratiﬁcation of the patient population,
and the regulatory approval and utility of the companion
diagnostic relies on approval of the therapeutic. Data shows
that factors pertaining to the therapeutic do not likewise
inﬂuence the price or sensitivity of the CDx. It appears that
the companion diagnostics market is governed by a diﬀerent
set of drivers than the pharmaceutical market because there is
no signiﬁcant relationship between economic factors for the two
industries.
The economic independence of CDx and therapeutic
may disincentivize development of companion diagnostics.
Personalized medicine is inherently a disruptive innovation and
FIGURE 4 | Number of companion diagnostics approved per year increases. Gray scatterplot shows the individual year of approval for each CDx in this study.
Black bar histogram shows the total number of companion diagnostics approved per year in this study.
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FIGURE 5 | Price ranges of companion diagnostics are wide. Lower boundary determined by Medicare reimbursement for the CPT code most closely
associated with test. Upper boundary determined typically by list price of company, obtained from a multiple of sources, such as published literature and personal
communication.
incentives to develop more personalized therapeutics may be
economic, as seen through high prices of personalized medicines
in oncology. However, the push toward greater investment in
CDx seems to be solely regulatory, because CDx do not share
in the same high prices and multiple doses as their expensive
corresponding therapeutics experience. Pricing for CDx would
indicate that diagnostic tests are valued as utility, much like a
needle that is used to inject a serum, and not as an integral
part of the therapeutic itself (Taube et al., 2009). However,
unlike the needle, which is universal and non-speciﬁc, the CDx
can direct a physician toward a speciﬁc course of treatment
and is as important to a treatment as the drug itself. While
companion diagnostics are clinical tools that can help physicians
decide the course of patient treatment, their pricing practices
are independent of the pricing practices for their corresponding
therapeutic, and this economic discrepancy might be a currently
overlooked barrier in the race to develop more personalized
therapeutics.
In context, there are also many other barriers to the
development and adoption of companion diagnostics.
Reimbursement uncertainty continues to create challenges
(Buchanan et al., 2013). Current reimbursement for companion
diagnostics relies on a complex system of CPT code stacking,
private health plan policies, evidence of clinical utility, and
cost of both the diagnostic and the treatment (Faulkner, 2009;
Trosman et al., 2011). Having a wide range for the ‘price’ of a
companion diagnostic indicates a lack of standardization in the
charges diﬀerent providers and insurers receive (Figure 5) and
could create an unwillingness to adopt complex therapies that
require not one, but two diﬀerent payments – one for the initial
companion diagnostic, and one for the following drug treatment.
Coverage and reimbursement for high-risk, high-reward
personalized treatments are often decided on a health plan
level and the existence of 100s of diﬀerent insurance plans
along with a national payer system for low-income, disabled,
and elderly Americans leads to fragmentation in access to life-
saving therapies (Redwood, 2002). Skepticism of the eﬃcacy
of companion diagnostics to predict responses to therapy
and uncertainty on the necessity of a companion diagnostic
slows reimbursement and creates challenges to the widespread
implementation of existing personalized therapies (Faulkner
et al., 2012).
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FIGURE 6 | Surface map for Herceptin CDx shows CDx have an expanding range of prices and greater sensitivity as time goes on. Z axis is specificity
of diagnostic and contour represents the price of the diagnostic in relation to its specificity during the year that it was approved. The more specific and expensive,
the further back and elevated the peak.
Additionally, the dominance of late stage competition and
lack of early stage competition within companion diagnostics
creates barriers to the innovation and development of the
companion diagnostics market (Amir-Aslani and Mangematin,
2010). Uncertainties in evaluating the utility of an assay when
clinical activity of the therapeutic or the relationship of the
biomarker to the mechanism of action of the therapeutic being
developed are major scientiﬁc challenges for multiple companion
diagnostics to be developed at once (Taube et al., 2009). The
high risk nature of CDx development incentivizes publicly
listed diagnostic companies to gravitate toward close-to-market
products capable of generating revenues in the short term to
satisfy the investment community instead of encouraging early
stage technologies that might deliver products far in the future
(Dickman, 2013).
The large upfront investment with low certainty in returns
for diagnostics does not encourage competition to occur between
companion diagnostics for a singular therapeutic before an
initial CDx reaches market. Competition can act as a positive
force to stabilize prices, and increase innovation (Batchelder and
Miller, 2006), and while companion diagnostics market does
not currently oﬀer a viable space for competition, it has the
potential to.
The predictive power of biomarkers varies between
indications and therapies (Taube et al., 2009), possibly opening
up space for more biomarkers with stronger analytical power to
enter into consideration for a therapeutics’ clinical trials. The
presence of some biomarkers, such as a particular gene mutation
in a CF mutation panel, or the detection of a KRAS mutation
status, allows for straightforward stratiﬁcation of patients into
dichotomous populations – a group that will respond to a
therapeutic and one that will not (Cheng et al., 2012). The
presence of other genes, such as HER2 or ALK (anaplastic
lymphoma kinase), is measured on a more continuous scale
and requires multiple runs and expert interpretation before
subsequent delineation into one particular treatment therapy
(Rogowski et al., 2010).
As seen in the case of Vectibix, for which clinicians began
with an EGFR-positive companion diagnostic, then added a
KRAS-negative companion diagnostic, a single test may not
be suﬃcient to correctly identify patient response levels. Well-
planned incremental evaluations of CDx/Tx pairs across phase I,
II, and III studies would ideally increase the eﬃciency of the drug
development process and response to therapeutic (Taube et al.,
2009; Jørgensen, 2013).
The inherent complexity of biomarker development and the
even more uncertain nature of drug development, innovation
models that encourage open competition during early stages
might work to increase success rates of therapeutics through
clinical trials and lower attrition values (Dickson and Gagnon,
2004). With the structure of co-development, competing
development of diagnostic methods is currently limited to
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TABLE 3 | Abbreviated list of limitations.
Limitations
• Recently approved CDx/Rx pairs
• Small amount of robust, publically available data
• Young market has a large number of variations
◦ Different entrance points for CDx (co-developed, individually adopted)
◦ Different classification as tests (FDA approved vs. LDT)
• Wide range of pricing for CDx
• Different endpoints for efficacy measures of therapeutics in different indications
• Rapidly changing regulatory and policy landscape
• Quickly developing technological advances
Select limitations are detailed in limitations section.
established contracts and investments from pharmaceutical
companies, but advances in technology and risk sharing models
might propel a more independent model for competition in the
future.
Limitations
This study has a number of limitations (Table 3). The main
limitation of this study is the maturity of the market and therefore
the small amount of robust, publically available data published
for each companion diagnostic and therapeutic. A young
industry has a large number of variations that make direct
comparisons diﬃcult. For instance, the point of stratiﬁcation for
one personalized therapeutic is not necessarily the same as the
point of stratiﬁcation of another personalized therapeutic. Some
companion diagnostics (Herceptin, Zelboraf, Xalkori) followed
a co-development model and received simultaneous CDx/Rx
approval from the FDA.
Other diagnostics (Vectibix, Ziagen, Selzentry, Kalydeco) were
classiﬁed as laboratory-developed tests (LDTs) at their conception
and received FDA approval after drug approval, or were adopted
into clinical practice without FDA review (Kahn et al., 2002;
Robertson et al., 2002). Given that LDTs undergo a less rigorous
clinical review through the Clinical Laboratory Improvement
Amendment (CLIA) regulatory pathway, they may have lower
cost requirements, leading to acute cost diﬀerences (McCormack
et al., 2014).
There are also two factors, CDx price and drug eﬃcacy,
with notable caveats and limitations. The factor ‘CDx price’ has
many contributing sources. There are multiple types of price
determinant for companion diagnostics, with a wide range of
pricing (Figure 6). The lower boundary of the pricing range is
attributed to Medicare National Limitation Amounts published
in the 2014 Clinical Laboratory Fee Schedule (Medicare, 2015)
while the upper boundary is generally attributable to company
list prices and hospital billings for outpatient, non-insured
individuals. Price variation also stems from the segmented
nature of Medicare reimbursement; while Medicare is a major
payer of high-risk, high-beneﬁt therapies, reimbursement diﬀers
depending on region and individual contracts.
Further fragmentation occurs on a providers level with
various hospitals stacking CPT codes in a multitude of ways
(Faulkner et al., 2012). Other forms of price determination
within the ranges in Figure 6 include private insurance, hospital
billings, and quotes from individual diagnostic companies.
Private insurance often takes example from Medicare limits, and
each has individual coverage policies that conditionally cover
treatments based on speciﬁc situations. Hospitals have opaque
pricing policies and diﬀer within regions. Companies typically
sell in bulk, rendering prices for individual companion diagnostic
tests diﬃcult to determine.
Due to these limitations, no one measure of price is
appropriate to represent the complexities in CDx price.
Therefore, for the purposes of this analysis, the price of the
CDx is deﬁned as the price most associated with the speciﬁc
companion diagnostic in published, pre-existing literature, and
is usually obtained as a measure of the cost of testing equipment
and compensation for labor and interpretation.
Therapeutic ‘eﬃcacy’ is deﬁned in the context of medical
interventions as “the performance of an intervention under ideal
and controlled circumstances” (Singal et al., 2014). Requirements
for an eﬃcacy trial include obtaining a readily available form
of the drug, recommending the drug to the identiﬁed target
population, and adhering to the drug prescription. The selected
personalized therapeutics in Table 1 address diﬀerent indications
and have diﬀerent endpoints – oncology generally has endpoints
of tumor reduction or disease free progression, cystic ﬁbrosis has
an endpoint of FEV (forced expiratory volume), and HIV has
endpoints of response rate or percentage of HIV infected RNA.
It is hard to ﬁnd equivalent measures of endpoints and clinical
utility across diﬀerent indications due to the varied nature of
disease and mechanisms of action of therapeutics. Despite the
diﬀerent measures of clinical endpoints, the clinical trials for
the personalized therapeutics meets the requirements for eﬃcacy
trials with equal access, targeted populations, and high adherence
rates. Therefore, data for drug eﬃcacy was appropriated from
published clinical trial information on patents, labels, and oﬃcial
FDA recommendations.
Additionally, unclear standards for clinical utility, rapid
advances in technology, uncertainty in relative eﬃciency
and cost-eﬀectiveness of CDx, and diﬀerences inherent to
diﬀerent indications create a variegated landscape for companion
diagnostics (Taube et al., 2009; Frueh, 2010; Davies et al., 2014;
Meadows et al., 2015).Given the rapidly evolving regulations
involved in the development of companion diagnostics and the
number of contracts, investments, and new therapeutics in the
drug development pipeline, this assessment should be considered
a snapshot of a quickly evolving system. There are many
complexities in the technological development and adoption of
companion diagnostics, and further research will be needed as the
landscape evolves.
CONCLUSION
Themarket for companion diagnostic development and adoption
is complex and diﬃcult to navigate. Where there is regulatory
pressure to co-develop companion diagnostics for the approval
of personalized therapeutics, there is a lack of parallel economic
collaboration to develop companion diagnostics. Factors that
pertain to the therapeutics market, such as market size and
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response rate do not drive the CDx market. The discrepancy
between the factors for the therapeutic/treatment and the
factors for companion diagnostics despite similar regulatory
standards, along with an uncertain reimbursement structure
and limited opportunities for early stage competition shows
that there is a misalignment in economic incentives that
could potentially discourage the development companion
diagnostics, for unspeciﬁed therapeutics. Further research
will be needed as the landscape for companion diagnostics
evolves.
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